CRIS Current Research Information System

TAVOLARI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.497
EU - Europa 1.923
AS - Asia 922
AF - Africa 144
SA - Sud America 18
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.507
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.481
GB - Regno Unito 415
SE - Svezia 322
IT - Italia 320
CN - Cina 306
VN - Vietnam 225
DE - Germania 223
SG - Singapore 197
CH - Svizzera 134
IE - Irlanda 127
IN - India 105
UA - Ucraina 79
FR - Francia 77
TG - Togo 55
RU - Federazione Russa 47
JO - Giordania 35
ZA - Sudafrica 33
FI - Finlandia 30
BE - Belgio 29
CI - Costa d'Avorio 29
EE - Estonia 26
BG - Bulgaria 24
NG - Nigeria 17
CA - Canada 15
GR - Grecia 11
HR - Croazia 11
NL - Olanda 9
CL - Cile 8
PL - Polonia 8
KR - Corea 7
IR - Iran 6
PS - Palestinian Territory 6
TR - Turchia 6
AT - Austria 5
BR - Brasile 5
RO - Romania 5
SC - Seychelles 5
UZ - Uzbekistan 5
JP - Giappone 4
TN - Tunisia 4
EC - Ecuador 3
ES - Italia 3
MY - Malesia 3
PT - Portogallo 3
SI - Slovenia 3
AU - Australia 2
BD - Bangladesh 2
DK - Danimarca 2
HU - Ungheria 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
SA - Arabia Saudita 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HK - Hong Kong 1
IL - Israele 1
KW - Kuwait 1
MC - Monaco 1
MX - Messico 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 5.507
Salva come PNG Salva come JPEG
Città #
Chandler 379
Southend 369
Fairfield 245
Dong Ket 213
Ashburn 171
Singapore 170
Houston 150
Dublin 127
Bern 125
Princeton 115
Wilmington 113
Ann Arbor 108
Woodbridge 108
Bologna 106
Seattle 97
Cambridge 90
Lomé 55
Jacksonville 47
New York 44
Nanjing 39
Westminster 38
Santa Clara 37
Amman 35
Berlin 34
Padova 30
Abidjan 29
Beijing 26
Brussels 26
Helsinki 26
Redmond 26
Jinan 25
San Diego 25
Sofia 24
Rome 20
Milan 19
Boardman 18
Medford 18
Abeokuta 17
Frankfurt am Main 15
Mülheim 14
Shenyang 14
Guangzhou 13
Florence 12
Hebei 12
Turin 12
Zhengzhou 12
Changsha 11
Fremont 11
Jiaxing 11
Toronto 11
Des Moines 10
Kuban 10
Nanchang 10
Saint Petersburg 10
Los Angeles 9
Olalla 9
Bühl 8
Dearborn 8
Norwalk 8
Redwood City 8
San Francisco 8
Haikou 7
Shanghai 7
Falls Church 6
Halhul 6
Hyderabad 6
Mountain View 6
Amsterdam 5
Bremen 5
London 5
Mahé 5
Mumbai 5
Ningbo 5
San Venanzo 5
São Paulo 5
Taiyuan 5
Vienna 5
Boydton 4
Council Bluffs 4
Fontanelice 4
Istanbul 4
Lappeenranta 4
Paris 4
Taizhou 4
Tianjin 4
Warsaw 4
Atlanta 3
Casalecchio di Reno 3
Castelfranco Emilia 3
Changchun 3
Chicago 3
Hangzhou 3
Kuala Lumpur 3
Kunming 3
Lanzhou 3
Lausanne 3
Lisbon 3
Monmouth Junction 3
Napoli 3
Phoenix 3
Totale 3.756
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 206
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 179
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 177
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 170
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 166
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 158
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 155
Simple and dendritic cyclam derivative. Photophysical properties, effect of protonation and Zn++ coordination, preliminary screening as inhibitors of tumor cell growth 142
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 141
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 140
Angiogenesis modulation in human umbilical endothelial vein (HUVE) cells by selected polychlorobiphenyls congeners is mediated by estrogen receptor alpha (ERα) binding. 134
Annellated pyrrole compounds for cancer management 127
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 127
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 125
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. 122
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 121
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner 120
In Reply 118
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 116
Annellated pyrrole compounds for cancer management 115
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 114
The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. 114
Immunomodulation by 17beta-estradiol in bivalve hemocytes. 113
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 112
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 112
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression 110
Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis 109
Cholangiocarcinoma: Epidemiology and risk factors 103
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 102
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 101
null 99
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 88
IN VIVO/IN VITRO AGED FIBROBLASTS TRIGGER MALIGNANT FEATURES IN NORMAL AND CANCER STEM/PROGENITOR CELLS OF THE MAMMARY GLAND 81
Carcinogenesis of Cholangiocarcinoma 80
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 77
TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells 75
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 75
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 72
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 71
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 69
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 66
The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines 65
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 63
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 63
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 63
Asbestos and Intrahepatic Cholangiocarcinoma 58
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 56
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 56
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 46
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma 45
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 45
Nivolumab: an investigational agent for the treatment of biliary tract cancer 40
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 39
Current and novel therapeutic opportunities for systemic therapy in biliary cancer 38
Evolution of the experimental models of cholangiocarcinoma 37
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 34
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 33
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 28
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. 22
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 21
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? 20
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 19
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 11
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. 9
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 3
Totale 5.716
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020851 0 0 0 58 89 102 135 137 156 72 46 56
2020/2021688 119 40 18 24 7 33 22 40 69 36 35 245
2021/20221.143 100 35 63 83 75 39 26 57 109 95 234 227
2022/20231.586 166 232 91 186 99 108 31 99 250 41 103 180
2023/2024422 54 59 22 34 34 97 14 25 10 31 15 27
2024/2025479 70 209 163 37 0 0 0 0 0 0 0 0
Totale 5.716